Status:
COMPLETED
Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer
Lead Sponsor:
Tony Bekaii-Saab
Collaborating Sponsors:
University of Michigan Rogel Cancer Center
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The primary purpose of this study is to define the maximum tolerated dose of combination docetaxel, gemcitabine, and capecitabine in patients with pancreatic cancer. Adverse effects will be measured i...
Detailed Description
Rationale: Single agent gemcitabine is considered standard care for patients with advanced pancreatic cancer. However, better treatments offering improved outcomes are needed for people with this dise...
Eligibility Criteria
Inclusion
- adenocarcinoma of the pancreas
- no prior chemo except adjuvant
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
- peripheral neuropathy \</= Gr. 1
Exclusion
- Pregnant/lactating females
- Uncontrolled heart disease, diabetes, psychiatric disorder
- Therapeutic doses of Warfarin
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT00320749
Start Date
December 1 2005
End Date
January 1 2011
Last Update
June 27 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States, 48109
2
Ohio State University
Columbus, Ohio, United States, 43210